Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer
Margaret M. Byrne(University of Iowa), Muhammad Furqan(University of Iowa), Sarah L. Mott(University of Iowa), Grerk Sutamtewagul(University of Iowa), Gerald H. Clamon(University of Iowa), Taher Abu Hejleh(University of Iowa), Arsenije Kojadinovic(University of Iowa), Gideon Zamba(University of Iowa), Jun Zhang(University of Iowa), William Zeitler(University of Iowa Hospitals and Clinics)
Cited by 3
Related Papers
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
|Nature Medicine|2024|234
Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study
|BJOG An International Journal of Obstetrics & Gynaecology|1995|215
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted <scp>EPOCH</scp>‐R
|British Journal of Haematology|2017|129